Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Flexion Therapeutics Inc. FLXN

Healthcare Drug Manufacturers - Major
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra... see more

Recent & Breaking News (NDAQ:FLXN)

12 Biggest Mid-Day Losers For Wednesday

Benzinga.com  November 16, 2016

Flexion Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire November 16, 2016

Flexion Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire November 15, 2016

Flexion Therapeutics Announces Presentation of Phase 3 Data Demonstrating that Extended-Release Zilretta™ Achieves Clinically Significant Improvement of Pain, Stiffness and Function in Patients with Osteoarthritis of the Knee

GlobeNewswire November 11, 2016

Flexion Therapeutics Reports Third Quarter 2016 Financial Results

GlobeNewswire November 7, 2016

Flexion Therapeutics Announces that Analysis from Phase 3 Clinical Trial of Zilretta™ for Osteoarthritis of the Knee to be presented at AAHKS

GlobeNewswire November 3, 2016

Flexion Therapeutics Reports Primary Endpoint Met in Clinical Trial Evaluating Investigational Drug Candidate Zilretta™ in Type 2 Diabetes Patients with Knee Osteoarthritis

GlobeNewswire November 1, 2016

Flexion Therapeutics to Report Third-Quarter 2016 Financial Results on November 7, 2016

GlobeNewswire October 28, 2016

Flexion Therapeutics Announces Appointment of John Magee as Vice President of Sales

GlobeNewswire September 29, 2016

Flexion Therapeutics Announces Appointment of Mark Stejbach to its Board of Directors

GlobeNewswire September 14, 2016

Flexion Therapeutics Announces Two Key Corporate Appointments

GlobeNewswire September 12, 2016

Flexion Therapeutics to Present at 2016 Wells Fargo Healthcare Conference

GlobeNewswire August 31, 2016

Flexion Therapeutics Reports Second-Quarter 2016 Financial Results

GlobeNewswire August 3, 2016

Flexion Therapeutics to Report Second-Quarter 2016 Financial Results on August 3, 2016

GlobeNewswire July 25, 2016

Flexion Therapeutics Adds Three New Executives in Key Roles to Support the Planned Commercial Launch of Zilretta™

GlobeNewswire July 6, 2016

Flexion Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire June 8, 2016

10 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  June 8, 2016

Flexion Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire June 7, 2016

Flexion Therapeutics Receives Positive Guidance from FDA on New Drug Application (NDA) Submission for Zilretta™ for Osteoarthritis of the Knee

GlobeNewswire May 26, 2016

Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors

GlobeNewswire May 20, 2016